News | November 15, 2010

Registry Created to Test Effectiveness of CTA

November 15, 2010 – The registry for a study designed to test the effectiveness of coronary computed tomographic angiography (CCTA) for diagnosing coronary artery disease (CAD) was announced at the American Heart Association (AHA) Scientific Session. The CONFIRM study spans six countries and will look at more than 27,000 patients.

Though the 2010 Expert Consensus on CCTA declared the evidence base “sufficiently mature” for clinical practice guidelines, CONFIRM addresses several gap areas.

“The international multicenter CONFIRM registry of more than 27,000 patients represents a highly collaborative effort of investigators at more than 12 centers who are examining the prognostic significance of coronary CT angiography findings,” said James K. Min, M.D., professor of medicine and radiology at the Cornell University Medical Center/New York Presbyterian Hospital and lead investigator of the CONFIRM registry. “The CONFIRM data definitively establish the prognostic value of CT-identified coronary artery disease and the risk of death associated with these findings. We hope that the CONFIRM data will allow for earlier detection of patients at risk for adverse coronary artery disease-related events and will result in improved treatment and outcomes of patients with coronary artery disease.”

There is a strong expectation that more long-term studies will be carried out in the future.

“CONFIRM is an important step in the validation of cardiac CT angiography,” said Matthew J. Budoff, M.D., FSCCCT, professor of medicine at the David Geffen School of Medicine at UCLA, director of cardiac CT at Los Angeles Biomedical Research Center at Harbor UCLA Medical Center and president of the Society of Cardiovascular Computed Tomography. “The size and scope of the project, coupled with the robust findings, should raise physician confidence that CT has an established role in clinical medicine.”

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init